GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiadis Pharma NV (FRA:K3P) » Definitions » ROC %

Kiadis Pharma NV (FRA:K3P) ROC % : -31.82% (As of Dec. 2020)


View and export this data going back to 2015. Start your Free Trial

What is Kiadis Pharma NV ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Kiadis Pharma NV's annualized return on capital (ROC %) for the quarter that ended in Dec. 2020 was -31.82%.

As of today (2024-05-26), Kiadis Pharma NV's WACC % is 6.07%. Kiadis Pharma NV's ROC % is -40.67% (calculated using TTM income statement data). Kiadis Pharma NV earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Kiadis Pharma NV ROC % Historical Data

The historical data trend for Kiadis Pharma NV's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiadis Pharma NV ROC % Chart

Kiadis Pharma NV Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
ROC %
Get a 7-Day Free Trial Premium Member Only -71.78 -96.23 -110.52 -144.45 -36.47

Kiadis Pharma NV Semi-Annual Data
Dec12 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -101.72 -100.76 -130.04 -57.99 -31.82

Kiadis Pharma NV ROC % Calculation

Kiadis Pharma NV's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2020 is calculated as:

ROC % (A: Dec. 2020 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2019 ) + Invested Capital (A: Dec. 2020 ))/ count )
=-34.105 * ( 1 - -0.14% )/( (72.782 + 114.487)/ 2 )
=-34.152747/93.6345
=-36.47 %

where

Kiadis Pharma NV's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2020 is calculated as:

ROC % (Q: Dec. 2020 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2020 ) + Invested Capital (Q: Dec. 2020 ))/ count )
=-28.476 * ( 1 - -0.09% )/( (64.68 + 114.487)/ 2 )
=-28.5016284/89.5835
=-31.82 %

where

Note: The Operating Income data used here is two times the semi-annual (Dec. 2020) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kiadis Pharma NV  (FRA:K3P) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Kiadis Pharma NV's WACC % is 6.07%. Kiadis Pharma NV's ROC % is -40.67% (calculated using TTM income statement data). Kiadis Pharma NV earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Kiadis Pharma NV ROC % Related Terms

Thank you for viewing the detailed overview of Kiadis Pharma NV's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kiadis Pharma NV (FRA:K3P) Business Description

Traded in Other Exchanges
N/A
Address
Paasheuvelweg 25A, Amsterdam, NLD, 1105 BP
Kiadis Pharma NV is a Netherlands based clinical-stage biopharmaceutical company. It is focused on research, development, and commercialization of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The company's product pipeline includes K-NK002, K-NK003, K-NK00X, and others.

Kiadis Pharma NV (FRA:K3P) Headlines

No Headlines